Literature DB >> 8909207

The effect of trauma on the ocular penetration of intravenous ciprofloxacin.

D V Alfaro1, S J Hudson, M M Rafanan, S T Moss, S D Levy.   

Abstract

PURPOSE: To study the intraocular pharmacokinetics of intravenously administered ciprofloxacin following eye trauma.
METHODS: Twenty-three New Zealand albino rabbits and 12 Yorkshire pigs each received a surgically induced scleral injury to the right eye. Following repair, each rabbit received a single 30-mg intravenous infusion of ciprofloxacin. Each pig received either two 200-mg doses or two 400-mg doses of intravenous ciprofloxacin given 12 hours apart. Vitreous and serum samples were harvested at 0.5, 1, 4, 6, and 12 hours after antibiotic administration in rabbits and 1 hour after the second dose in pigs. Bioassays for ciprofloxacin were performed on each sample, and results were statistically compared by t test. The untraumatized left eye in each animal served as a control.
RESULTS: The mean vitreous concentration of ciprofloxacin in traumatized rabbit eyes was 0.37 microgram/ml. This level was sustained above levels in control eyes (0.18 microgram/ml) for at least 4 hours following antibiotic administration. In control eyes, intravitreal levels peaked at 1 hour. Mean vitreous concentrations +/- SD in traumatized pig eyes were 0.091 +/- 0.017 microgram/ml in swine that had received 200-mg doses of ciprofloxacin vs 0.312 +/- 0.153 microgram/ml in swine that had received 400-mg doses (P = .02). Mean vitreous concentrations of ciprofloxacin in control eyes were not affected by increasing dosage.
CONCLUSION: In both animal models, experimental surgical trauma increased intravitreal ciprofloxacin delivery. In addition, systemically administered ciprofloxacin achieved intravitreous levels exceeding minimum inhibitory concentrations for common ocular pathogens, suggesting a role for ciprofloxacin in the prophylaxis of posttraumatic endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909207     DOI: 10.1016/s0002-9394(14)70486-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration.

Authors:  E García-Vázquez; J Mensa; M Sarasa; Y López; P D Couchard; D Soy; J R Fontenla
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

2.  Penetration of moxifloxacin into the human aqueous humour after oral administration.

Authors:  G Kampougeris; A Antoniadou; E Kavouklis; Z Chryssouli; H Giamarellou
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 3.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

Review 4.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.

Authors:  N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans.

Authors:  O Cekiç; C Batman; U Yaşar; N E Başci; O Zilelioğlu; A Bozkurt
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

8.  Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Authors:  Seenu M Hariprasad; William E Mieler; Gaurav K Shah; Kevin J Blinder; Rajendra S Apte; Nancy M Holekamp; Matthew A Thomas; Jingduan Chi; Randall A Prince
Journal:  Trans Am Ophthalmol Soc       Date:  2004

9.  Signal Detection Between Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korean Healthcare Database Between 2004 and 2015.

Authors:  Yeon-Hee Baek; Sang Jun Park; Sohyun Jeong; In-Sun Oh; Han Eol Jeong; Kyu Hyung Park; Ju-Young Shin
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

10.  Vitreous penetration of orally administered gatifloxacin in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2002
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.